Further results from TIVO-1 study of tivozanib (Aveo Oncology/ Astellas) for Renal Cell Carcinoma treatment
AVEO Oncology and Astellas have reported final overall survival (OS) results from the comparative Phase III TIVO-1 trial with tivozanib in the treatment of advanced Renal Cell Carcinoma (RCC). The protocol-specified analysis showed that the median OS of 28.8 months (95% CI: 22.5-NA) for the oral VEGF inhibitor was less than the 29.3 months (95% CI: 29.3-NA) for Nexavar (sorafenib) from Bayer/Onyx Pharma. No statistical difference between the two arms was observed (HR=1.245, p=0.105).
Tivozanib has reported earlier a statistically significant improvement in progression-free survival (PFS) - to 11.9 months versus 9.1 months - over Nexavar in the 517-patient trial, which AVEO and Astellas note is the first superiority study in first-line advanced RCC in which an investigational agent has demonstrated such a benefit over an approved targeted agent.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins